Action of antiproteases on pancreatic cancer cells

Journal of the Pancreas

Volumn 8, Issue 4, 2007, Pages 479-487

  Uchima, Yasutake ^a   Sawada, Tetsuji ^a   Harikawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Matrix metalloproteinase 2; Pancreatic neoplasms; Transforming growth factor beta; Trypsinogen; Urinary plasminogen activator; Vascular endothelial growth factors

Indexed keywords

GABEXATE MESILATE; GELATINASE A; GELATINASE B; GROWTH FACTOR; PROTEINASE INHIBITOR; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; TRYPSINOGEN; UROKINASE; VASCULOTROPIN;

ACUTE PANCREATITIS; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL LINE; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FEMALE; GENE OVEREXPRESSION; GENE SYNTHESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER METASTASIS; METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR MATRIX; GABEXATE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PEPTIDE HYDROLASES; PROTEASE INHIBITORS; RECEPTOR, PAR-2; TRANSFORMING GROWTH FACTOR BETA1;

EID: 34547950952     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (38)

1. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72:1-22.
2. Clark RL. Systemic cancer and the metastatic process. Cancer 1979; 43:790-7.
3. Uchima Y, Sawada T, Nishihara T, Maeda K, Ohira M, Hirakawa K. Inhibition and mechanism of action of a protease inhibitor in human pancreatic cancer cells. Pancreas 2004; 29:123-31.
4. Teraoka H, Sawada T, Yamashita Y, Nakata B, Ohira M, Ishikawa T, et al. TGF-beta1 promotes liver metastasis of pancreatic cancer by modulating the capacity of cellular invasion. Int J Oncol 2001; 19:709-15.
5. Cantero D, Friess H, Deflorin J, Zimmermann A, Brundler MA, Riesle E, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 1997; 75:388-95.
6. Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G, Gress TM. TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer 2001; 93:204-11.
7. Uchima Y, Sawada T, Nishihara T, Umekawa T, Ohira M, Ishikawa T, et al. Identification of a trypsinogen activity stimulating factor produced by pancreatic cancer cells: its role in tumor invasion and metastasis. Int J Mol Med 2003; 12:871-8.
8. Tajima H, Ohta T, Elnemr A, Yasui T, Kitagawa H, Fushida S, et al. Enhanced invasiveness of pancreatic adenocarcinoma cells stably transfected with cationic trypsinogen cDNA. Int J Cancer 2001; 94:699-704.
9. Maatta M, Soini Y, Liakka A, Autio-Harmainen H. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res 2000; 6:2726-34.
10. Ellenrieder V, Alber B, Lacher U, Hendler SF, Menke A, Boeck W, et al. Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer 2000; 85:14-20.
11. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64:327-36.
12. Yang X, Staren ED, Howard JM, Iwamura T, Bartsch JE, Appert HE. Invasiveness and MMP expression in pancreatic carcinoma. J Surg Res 2001; 98:33-9.
13. Nagakawa Y, Aoki T, Kasuya K, Tsuchida A, Koyanagi Y. Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer. Pancreas 2002; 24:169-78.
14. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000; 60:636-43.
15. Yu HR, Schultz RM. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res 1990; 50:7623-33.
16. Stahl A, Mueller BM. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 1994; 54:3066-71.
17. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993; 53:5365-9.
18. Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 1992; 10:145-55.
19. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284:67-8.
20. Baramova EN, Bajou K, Remacle A, L'Hoir C, Krell HW, Weidle UH, et al. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS lett 1997; 405:157-62.
21. Brodrick J, Largman C, Hsiang M, Johnson J, Geokas M. Structural basis for the specific activation of human cationic trypsinogen by human enteropeptodase. J Biol Chem 1978; 25:2737-42.
22. Williams SJ, Gotley DC, Antalis TM. Human trypsinogen in colorectal cancer. Int J Cancer 2001; 93:67-73.
23. Miyata S, Miyagi Y, Koshikawa N, Nagashima Y, Kato Y, Yasumitsu H, et al. Stimulation of cellular growth and adhesion to fibronectin and vitronectin in culture and tumorigenicity In nude mice by overexpression of trypsinogen in human gastric cancer cells. Clin Exp Metastasis 1998; 16:613-22.
24. Nystedt S, Emilsson K, Wahlestedt C, Sundelin J. Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci U S A 1994; 91:9208-12.
25. Kawabata A, Kuroda R, Nishida M, Nagata N, Sakaguchi Y, Kawao N, et al. Protease-activated receptor-2 (PAR-2) in the pancreas and parotid gland: Immunolocalization and involvement of nitric oxide in the evoked amylase secretion. Life Sci 2002; 71:2435-46.
26. Bohm SK, Kong W, Bromme D, Smeekens SP, Anderson DC, Connolly A, et al. Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J 1996; 314:1009-16.
27. Nguyen TD, Moody MW, Steinhoff M, Okolo C, Koh DS, Bunnett NW. Trypsin activates pancreatic duct epithelial cell ion channels through proteinase-activated receptor-2. J Clin Invest 1999; 103:261-9.
28. Kawabata A, Nishikawa H, Kuroda R, Kawai K, Hollenberg MD. Proteinase-activated receptor-2 (PAR-2): regulation of salivary and pancreatic exocrine secretion in vivo in rats and mice. Br J Pharmacol 2000; 129:1808-14.
29. Shimamoto R, Sawada T, Uchima Y, Inoue M, Kimura K, Yamashita Y, et al. A role for protease-activated receptor-2 in pancreatic cancer cell proliferation. Int J Oncol 2004; 24:1401-6.
30. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev 1996; 7:93-102.
31. Akhurst RJ, Balmain A. Genetic events and the role of TGF beta in epithelial tumour progression. J Pathol 1999; 187:82-90.
32. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 1996; 10:2462:77.
33. Rowland-Goldsmith MA, Maruyama H, Matsuda K, Idezawa T, Ralli M, Ralli S, Korc M. Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol Cancer Ther 2002; 1:161-7.
34. Odekon LE, Blasi F, Rifkin DB. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta. J Cell Physiol 1994; 158:398-407.
35. Teraoka H, Sawada T, Nishibara T, Yashiro M, Ohira M, Ishikawa T, et al. Enhanced VEGF production and decreased immunogenicity induced by TGF-beta 1 promote liver metastasis of pancreatic cancer. Br J Cancer 2001; 85:612-7.
36. Tamura Y, Hirado M, Okamura K, Minato Y, Fujii S. Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r-, and C1 esterase. Biochim Biophys Acta 1977; 484:417-22.
37. Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 1999; 79:1553-63.
38. Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Buchler MW, Korc M. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 1997; 3:1309-16.